Video

The Evolving Treatment Landscape in SCLC

Beth Sandy, MSN, CRNP, discusses the evolving treatment landscape in small cell lung cancer.

Beth Sandy, MSN, CRNP, thoracic oncology nurse practitioner, Abramson Cancer Center, University of Pennsylvania, discusses the evolving treatment landscape in small cell lung cancer (SCLC). 

Single-agent immunotherapy had shown encouraging data in the second- and third-line settings. However, the emergence of chemoimmunotherapy in the frontline setting has revolutionized the treatment landscape, says Sandy.

In 2019, the FDA approved the combination of atezolizumab (Tecentriq), carboplatin, and etoposide for the frontline treatment of patients with extensive-stage SCLC. Moreover, in March 2020, the FDA approved the combination of durvalumab (Imfinzi) and etoposide and either carboplatin or cisplatin in the same setting.

On June 15, 2020, the FDA grated an accelerated approval to lurbinectedin (Zepzelca) for patients with metastatic SCLC who have disease progression following platinum-based chemotherapy. Each FDA approval is a welcome addition to the armamentarium, Sandy concludes. 

Related Videos
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.